Clinical Trial Update: CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of CMP-001 in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma has been terminated; results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CMP-001
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: TERMINATED | Results posted: 2025-04-08